Dr Alizadeh completed his PhD in Biophysics and MD at Stanford in 2003, under mentorship of Pat Brown (Stanford Biochemistry) and Lou Staudt (NCI/NIH). Supported by the Howard Hughes Medical Institute (HHMI) and NIH Medical Scientist Training Program (MSTP), he built the Lymphochip DNA microarray platform. He and his colleagues used this platform to profile gene expression in diffuse large B cell lymphoma (DLBCL), and many other tumors. This work led to the discovery of DLBCL subtypes, and a framework for their cell of origin. Following his clinical subspecialty Hematology and Medical Oncology training at Stanford, he completed his postdoctoral studies with Ron Levy and Irv Weissman. During this time, he worked on molecular outcome prediction in DLBCL, developing statistical frameworks for identification of small numbers of genes for robust risk stratification and prognosis. Working with Irv Weissman, he identified CD47 expression as an adverse prognostic factor in non-Hodgkin lymphomas, and a therapeutic target of novel monoclonal antibodies that synergize to eradicate tumors. The Alizadeh lab studies genomic biomarkers of tumors, whether detected through biopsy of primary tissues, or non-invasively through monitoring blood using circulating tumor DNA (ctDNA). His group has developed several novel methods for ctDNA detection including Cancer Personalized Profiling by deep Sequencing (CAPP-Seq), EPIC-Seq, RARE-Seq, and PhasED-Seq, and developed a novel cell deconvolution framework (CIBERSORT/x), applying it broadly to human cancers (PRECOG; EcoTyper). His group applies such genomic tools for early detection, diagnosis, and monitoring of diverse tumors. In this effort, his group builds and employ tools from functional genomics, computational biology, molecular genetics, and mouse models.